非小细胞肺癌中程序性细胞死亡蛋白1与程序性死亡配体1相互作用的原位检测作为免疫检查点抑制应答的功能性预测指标
本研究采用第二代原位邻近连接技术检测16种癌症组织、早期NSCLC组织芯片及140例晚期NSCLC诊断活检中PD1-PD-L1相互作用。早期NSCLC中仅约半数PD-L1和PD1表达可检测的病例存在相互作用,EGFR突变肿瘤中水平显著更低;ICI治疗患者中较高相互作用与完全缓解和更长生存相关,优于标准PD-L1表达检测。
要点
- 早期NSCLC中仅约半数PD-L1和PD1表达可检测的病例存在PD1-PD-L1相互作用。
- EGFR突变肿瘤中PD1-PD-L1相互作用水平显著更低。
- ICI治疗NSCLC中较高PD1-PD-L1相互作用与完全缓解和更长生存相关,优于标准PD-L1检测。
核心结论
- 研究提出从静态生物标志物定量转向评估活跃免疫通路的功能性诊断概念,可应用于微小肺活检并推广至其他免疫检查点。
- 结果提示存在协同的ICI耐药机制,强调需要联合诊断与治疗。
研究设计与样本
- 应用第二代原位邻近连接技术检测16种不同癌症类型的诊断组织样本中PD1-PD-L1相互作用。
- 检测手术切除早期NSCLC的组织芯片。
- 检测140例接受和未接受ICI治疗的晚期NSCLC患者的诊断活检。
- 采用RNA测序分析识别潜在耐药机制。
主要发现
- 早期NSCLC中仅约半数PD-L1和PD1表达可检测的病例存在PD1-PD-L1相互作用,EGFR突变肿瘤中水平显著更低。
- PD1-PD-L1相互作用水平在不同癌症类型间存在差异,与已报道的ICI应答率一致。
- ICI治疗的NSCLC患者中,较高PD1-PD-L1相互作用与完全缓解和更长生存相关,优于标准PD-L1表达检测。
- 尽管PD1-PD-L1相互作用高但未对ICI应答的患者,表现出基质免疫介质EOMES、HAVCR1/TIM-1、JAML、FCRL1的额外表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have transformed lung cancer treatment, yet their effectiveness seem restricted to certain patient subsets. Current clinical stratification on the basis of programmed death ligand 1 (PD-L1) expression offers limited predictive value. Given the mechanism of action, directly detecting spatial programmed cell death protein 1 (PD1)-PD-L1 interactions might yield more precise insights into immune responses and treatment outcomes. METHODS: We applied a second-generation in situ proximity ligation assay to detect PD1-PD-L1 interactions in diagnostic tissue samples from 16 different cancer types, a tissue microarray with surgically resected early-stage NSCLC, and finally diagnostic biopsies from 140 patients with advanced NSCLC with and without ICI treatment. RNA sequencing analysis was used to identify potential resistance mechanisms. RESULTS: In the early-stage NSCLC, only approximately half of the cases with detectable PD-L1 and PD1 expression exhibited PD1-PD-L1 interactions, with significantly lower levels in EGFR-mutated tumors. Interaction levels varied across cancer types, aligning with reported ICI response rates. In ICI-treated patients with NSCLC, higher PD1-PD-L1 interactions were linked to complete responses and longer survival, outperforming standard PD-L1 expression assays. Patients who did not respond to ICIs despite high PD1-PD-L1 interactions exhibited additional expression of stromal immune mediators (EOMES, HAVCR1/TIM-1, JAML, FCRL1). CONCLUSION: Our study proposes a diagnostic shift from static biomarker quantification to assessing active immune pathways, providing more precise ICI treatment. This functional concept applies to tiny lung biopsies and can be extended to further immune checkpoints. Accordingly, our results indicate concerted ICI resistance mechanisms, highlighting the need for combination diagnostics and therapies.
引用
- Lindberg A, Muhl L, Yu H, et al. In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC. J Thorac Oncol. 2024. PMID: 39743139. doi:10.1016/j.jtho.2024.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。